[
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT true about Bleomycin?",
    "options": [
      "It causes dose-related pulmonary fibrosis",
      "It intercalates DNA to inhibit replication",
      "It induces single and double-strand DNA breaks",
      "It is excreted primarily via the kidneys"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "All of the following are true regarding Mitomycin C EXCEPT:",
    "options": [
      "It is cell-cycle nonspecific",
      "It cross-links DNA",
      "It is activated via enzymatic reduction",
      "It works best in oxygen-rich environments"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Mitomycin C requires what process for activation?",
    "options": [
      "Enzymatic reduction",
      "Glucuronidation",
      "Dephosphorylation",
      "CYP450 oxidation"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "Bleomycin-induced pulmonary toxicity is most associated with:",
    "options": [
      "Hepatic metabolism",
      "Rapid IV infusion",
      "Cardiac co-morbidities",
      "Age and cumulative dose"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "All of the following are mechanisms of Anthracycline-induced cytotoxicity EXCEPT:",
    "options": [
      "Free radical formation",
      "DNA intercalation",
      "Topoisomerase II inhibition",
      "Microtubule stabilization"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Mitomycin C is especially effective in combination with radiotherapy due to:",
    "options": [
      "Cross-resistance reversal",
      "Anti-angiogenic synergy",
      "Ability to sensitize hypoxic tumor cells",
      "Enhanced DNA repair activation"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is NOT an effect of Doxorubicin cardiotoxicity?",
    "options": [
      "Inhibition of ryanodine receptor",
      "Dilated cardiomyopathy",
      "Interference with microtubules",
      "Free radical formation"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Why is Idarubicin preferred over Daunorubicin in AML induction therapy?",
    "options": [
      "Less cardiotoxicity",
      "Higher intracellular activity",
      "Higher oral bioavailability",
      "Greater myelosuppression"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is a semisynthetic analog of Daunorubicin, used in AML?",
    "options": [
      "Idarubicin",
      "Doxorubicin",
      "Epirubicin",
      "Mitomycin C"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "What is the main mechanism of DNA damage by Bleomycin?",
    "options": [
      "Alkylation of DNA",
      "Formation of DNA-Fe(II) complex causing strand breaks",
      "Blocking mitotic spindle",
      "Topoisomerase I inhibition"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "What is the main mechanism of action of Anthracyclines?",
    "options": [
      "Microtubule depolymerization",
      "Topoisomerase II inhibition and DNA intercalation",
      "Alkylation of guanine residues",
      "Inhibition of topoisomerase I"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "What is the active metabolite of Mitomycin C that cross-links DNA?",
    "options": [
      "Epirubicinol",
      "SN-38",
      "Mitosene",
      "Daunosamine"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "The most serious side effect of Bleomycin is:",
    "options": [
      "Hemorrhagic cystitis",
      "Cardiotoxicity",
      "Ototoxicity",
      "Pulmonary fibrosis"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which Anthracycline is specifically indicated for node-positive breast cancer?",
    "options": [
      "Doxorubicin",
      "Epirubicin",
      "Daunorubicin",
      "Idarubicin"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which agent is used as a cardioprotective drug to reduce Doxorubicin toxicity?",
    "options": [
      "Leucovorin",
      "Mesna",
      "Filgrastim",
      "Dexrazoxane"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which phase of the cell cycle is Bleomycin most active in?",
    "options": [
      "G2 and M",
      "G0",
      "S",
      "G1 and S"
    ],
    "correct_option": 0
  },
  {
    "topic": "pharmacology",
    "question": "How is Bleomycin primarily excreted?",
    "options": [
      "Biliary",
      "Lung metabolism",
      "Renal",
      "Skin excretion"
    ],
    "correct_option": 2
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following explains why Doxorubicin can cause late-onset heart failure?",
    "options": [
      "DNA intercalation in cardiomyocytes",
      "Blockade of Na\u207a/K\u207a ATPase",
      "Irreversible inhibition of cardiac topoisomerase I",
      "Accumulation of iron-mediated free radicals in cardiac mitochondria"
    ],
    "correct_option": 3
  },
  {
    "topic": "pharmacology",
    "question": "Which cytotoxic antibiotic has limited efficacy in solid tumors but is effective in AML?",
    "options": [
      "Bleomycin",
      "Daunorubicin",
      "Mitomycin C",
      "Epirubicin"
    ],
    "correct_option": 1
  },
  {
    "topic": "pharmacology",
    "question": "Which of the following is a serious side effect of Mitomycin C?",
    "options": [
      "Dilated cardiomyopathy",
      "Neurotoxicity",
      "Microangiopathic hemolytic anemia",
      "Pulmonary fibrosis"
    ],
    "correct_option": 2
  }
]
